NanoVibronix touts lowered UTIs in interim UroShield study results

NanoVibronix (NSDQ:NAOV) today released interim results from a trial of its UroShield ultrasound device designed to prevent bacteria and biofilms from forming on urinary catheters, touting a low rate of catheter-acquired urinary tract infections. The Uroshield device from the Elmsford, N.Y.-based company is designed to decrease pain and discomfort associated with urinary catheter use while also preventing bacterial colonization and biofilm on indwelling catheters to reduce UTIs. The 51-patient trial examined patients at 5 nursing facilities, with 26 patients being treated with the UroShield and 25 in a control group receiving the standard of care. All patients in the trial had been treated for at least 1 incident of CAUTIs requiring antibiotics 6-months prior to the trial, the company said. At 90-days, 52% of the control group individuals had developed a CAUTI which required antibiotic intervention, while only 4% of the UroShield patients acquired one. All subjects were initially recorded with a colony count of greater 100,000 CFU cultured from their urinary tract, NanoVibronix said. UroShield patients showed reductions in this count, however, with 15 patients having counts reduced to 10,000 CFU at 90 days and 10 patients reduced to 1,000 CFU. “We are pleased to report the interim results of this latest study, demonstrating a material reduction in the rate of CAUTI. These successful results reinforce our earlier data demonstrating a significant reduction in infection r...
Source: Mass Device - Category: Medical Devices Authors: Tags: Catheters Clinical Trials Urology nanovibronix Source Type: news